Alexion Pharmaceuticals, Inc. (ALXN) failed to extend gains with the stock declining -2.98% or $-3.94 to close the day at $128.38 on light trading volume of 2.82M shares, compared to its three month average trading volume of 3.17M. The New Haven Connecticut 06510 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -12.05%, compared to the industry which has advanced 7.3% over the same period. With RSI of 46.38, the stock should still continue to rise and get closer to its one year target estimate of $167.93, making it a hold for now.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
The Mosaic Company (MOS) retreated with the stock falling -0.73% or $-0.23 to close at $31.45 on light trading volume of 2.81M compared its three months average trading volume of 5.03M. The Plymouth Minnesota 55441 based company operating under the Agricultural Chemicals industry has been trending up for the last 52 weeks, with the shares price now 36.87% up for the period and up by 7.23% so far this year. With price target of $27.26 and a 48.74% rebound from 52-week low, The Mosaic Company has plenty of upside potential, making it a hold with a view buy.
The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients primarily for the agricultural industry worldwide. The company operates through three segments: Phosphates, Potash, and International Distribution. It owns and operates mines, which produce concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products; and phosphate-based animal feed ingredients primarily under the Biofos and Nexfos brand names. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant, as well as fluorosilicic acid for water fluoridation. In addition, it provides nitrogen-based crop nutrients and animal feed ingredients, and other ancillary services; and purchases and sells phosphates, potash, and nitrogen products. The company sells its products to wholesale distributors, retail chains, cooperatives, independent retailers, and national accounts. The Mosaic Company was founded in 2004 and is headquartered in Plymouth, Minnesota.
The Goldman Sachs Group, Inc. (GS) failed to extend gains with the stock declining -0.11% or $-0.26 to close the day at $230.41 on lower than average trading volume of 2.77M shares, compared to its three month average trading volume of 4.36M. The New York New York 10282 based company has been outperforming the investment brokerage – national companies by 29.5354% for last three months and its recent gains have offset losses to -3.78% YTD, versus the investment brokerage – national industry which is up 0.65% for the same period. The RSI of 43.07 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment management company worldwide. It operates through four segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Management. The Investment Banking segment provides financial advisory services, such as strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, spin-offs, and risk management; and underwriting services, including public offerings and private placements of various securities and other financial instruments, as well as derivative transactions entered into with public and private sector clients. The Institutional Client Services segment is involved in client execution activities related to making markets in interest rate products, credit products, mortgages, currencies, commodities, and equities; and provides securities services, such as financing, securities lending, and other prime brokerage services, as well as markets in and clears client transactions on primary stock, options, and futures exchanges. The Investing & Lending segment invests in and originates longer-term loans to provide financing to clients; and makes investments in debt securities and loans, public and private equity securities, and real estate entities. The Investment Management segment offers investment management products and services; and wealth advisory services, including portfolio management and financial counseling, and brokerage and other transaction services. The company serves corporations, financial institutions, governments, and individuals. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.